Depomed — Investor Presentation (February 2018)
19 slides from Depomed's investor presentation, Feb 14, 2018
Slide 1: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("Act"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor"
Slide 2: Principles Guiding the Way We Do Business
Principles Guiding the Way We Do Business PUTTING the Patient First PRODUCTIVITY Aimed at Improving Effectiveness Across the Business PROFITABILITY in Line with Our Peer Group 3 February 2018
Slide 3: A Clear Strategy for Growth
A Clear Strategy for Growth Executing on a Three Pillar Growth Strategy 4 MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Anno
Slide 4: Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA Franchise
Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA® Franchise 5 MAINTAIN With the January closing, Collegium Pharmaceutical obtained the rights to commercialize NUCYNTA® Depomed retains ownership of the NDAs and be responsible for NUCYNTA® product supply Depomed maintains responsibility
Slide 5: Industrial Logic is Clear and Compelling: Financially, Strategically and Patient-Focused
Industrial Logic is Clear and Compelling: Financially, Strategically and Patient-Focused Depomed Collegium Financially Immediately Accretive Improves Absolute EBIDTA Strategically Collegium as a Leader in Pain and Depomed Ability to Focus on Neurology/ Orphan Drugs Allows Significant Cost Synergies
Slide 6: Collegium: Ideal Partner to Take NUCYNTA to the Next Level
Collegium: Ideal Partner to Take NUCYNTA® to the Next Level Recognized as an emerging leader in pain management and committed to building a leading pain company Xtampza® ER is the fastest growing Extended Release branded opioid Strong home office, commercial and managed care infrastructures Salesfor
Slide 7: Depomed $135 Million Annual Payment - Highly Secure and Independent of Collegium's Financial Position
Depomed $135 Million Annual Payment - Highly Secure and Independent of Collegium’s Financial Position 8 100% 100% Gross Sales go into lock box Includes a $33.75M letter of credit should Collegium fall below the minimum Special Purpose Vehicle (SPV) Bankruptcy Protected 35% Daily sweep of Gross Sales
Slide 8: Potential for EBIDTA Improvement
Potential for EBIDTA Improvement Assumed NUCYNTA Net Sales* 9 $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Grünenthal ($3.2) - $1.2 Net EBIDTA Improvement $46.8 $37 $25.2 Guidance to be Provided in 2018 *For illustrative
Slide 9: Grow Our Neurology and Pain Businesses
GROW Grow Our Neurology and Pain Businesses September marked the completed relaunch of our Neurology salesforce with 90 representatives Provides proper support to highly-promotionally sensitive products Gralise® and CAMBIA ® Creates credible platform to expand with new products Committed to adding a
Slide 10: Build A New Specialty Business
Build A New Specialty Business Establishment of a New Specialty Products Business Unit Mark Booth as General Manager brings 30+ years of biopharma experience Objective is to build a portfolio of specialty/orphan drugs addressing the unmet needs of the patient, physician and payors Provides a platfor
Slide 11: Transformational Transaction Creates New Specialty Business
Transformational Transaction Creates New Specialty Business Depomed/ Slán Medicinal Holdings Limited Acquisition of Cosyntropin (Synthetic ACTH Depo) provides a late-stage, high-value product Depomed is the exclusive licensee for United States Current U.S. market is led by H.P. Acthar® Gel (Natural
Slide 12: Headquarters Restructuring and Relocation Aligns with New Business Model
Headquarters Restructuring and Relocation Aligns with New Business Model Headquarters Relocation in 2018: Evaluating Mid-West and East Coast Sites Provides Improved Access to Pharmaceutical Talent Current Footprint: 60,000 square feet housing 120 employees 380 person salesforce New Footprint: Approx
Slide 13: Gralise: Differentiated within the 71MM Annual Prescription Market
Gralise®: Differentiated within the 71MM Annual Prescription Highly Promotionally Sensitive Market Indication Management of post-herpetic neuralgia Performance 2016 net sales of $88 million 3Q 2017 net sales of $21 million Clinical Differentiation Only once-daily formulation of gabapentin Significan
Slide 14: Cambia: Differentiated within the 15MM Annual Prescription Market
Cambia®: Differentiated within the 15MM Annual Prescription Highly Promotionally Sensitive Market Indication Performance Clinical Differentiation Acute migraine attacks in adults 2016 net sales of $31 million 3Q 2017 net sales of $8 million Only single-agent in therapeutic class for acute migraine R
Slide 15: Zipsor: Differentiated within the 11MM Annual Prescription Market
Zipsor®: Differentiated within the 11MM Annual Prescription Highly Promotionally Sensitive Market Indication Mild to moderate acute pain in adults Performance 2016 net sales of $28 million 3Q 2017 net sales of $3.2 million Clinical Differentiation Only prescription NSAID in gel cap form Unique ProSo
Slide 16: Milestones Driving Growth in 2018 and Beyond
NUCYNTA® Commercialization Agreement: Close Agreement with Collegium Pharmaceutical Synthetic Cosyntropin (Synthetic ACTH Depot): Commenced Investigational New Drug (IND) Trial in Infantile Spasms Purdue Litigation: Pre-Trial Conference to Set Trial Date Milestones Driving Growth in 2018 and Beyond
Slide 17: Depomed's Transformation is Well Underway
180 Days Ago NUCYNTA and Lazanda franchises placed Depomed with a heavy opioid concentration in a volatile market NUCYNTA field force needed to be downsized and retargeted with significant dislocation risk Promotionally-sensitive neurology products under resourced with ~ 40 person field force No Thi
Slide 18: Our Commitment to Shareholders
Our Commitment to Shareholders 19 Execute on a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Grow Our Neurology and Pain Businesses and Build a New Specialty Business Leverage Opportunities to Drive Superior Profitability Committed to Putting the Patient First February 2018
Slide 19: Execute on a Clear Strategy
Execute on/a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Committed to Grow OuPNeurology and Pain Businesses and Build a New Specialty Business Putting the Patient First Seoeromen